Multidimensional efficacy characterization of xeligekimab in moderate-to-severe plaque psoriasis: regional responses, treatment targets, and patient-reported outcomes from a randomized controlled trial.
Frontiers in immunology · 2026
Abstract e pubblicazione originale
L’abstract è consultabile nella fonte originale. Non viene ripubblicato qui perché non risulta verificata una licenza compatibile.
Leggi nella fonte originale ↗Parole chiave
AdultFemaleHumansMaleMiddle AgedAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedDouble-Blind MethodInterleukin-17Patient Reported Outcome MeasuresPsoriasisQuality of LifeSeverity of Illness IndexTreatment Outcomepatient-reported outcomesplaque psoriasispost hoc analysistreatment targetsxeligekimab
Come citare questo studio
Kun Huang, Yi Zhao, Chunjun Yang, Jianzhong Zhang. (2026). Multidimensional efficacy characterization of xeligekimab in moderate-to-severe plaque psoriasis: regional responses, treatment targets, and patient-reported outcomes from a randomized controlled trial.. Frontiers in immunology. DOI: 10.3389/fimmu.2026.1917350
Consulta la pubblicazione originale ↗